Exelixis, Inc. (EXEL)

44.63 +0.59 (+1.34%) USD  |  NASDAQ  |  Jan 12, 11:12
More

Exelixis Underperform Recommendations

Underperform Recommendations Chart

View Underperform Recommendations for EXEL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Underperform Recommendations Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Underperform Recommendations Range, Past 5 Years

View Underperform Recommendations Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Underperform Recommendations Benchmarks

View Underperform Recommendations Benchmarks
Start Trial
Vanda Pharmaceuticals, Inc. Upgrade
ADMA Biologics, Inc. Upgrade
Aldeyra Therapeutics, Inc. Upgrade
Natera, Inc. Upgrade
Merck & Co., Inc. Upgrade